80 related articles for article (PubMed ID: 834952)
1. [Blood uric acid in myeloma].
Caplain-Dandine F; Kahn MF; de Sèze S
Rev Rhum Mal Osteoartic; 1977 Jan; 44(1):1-4. PubMed ID: 834952
[TBL] [Abstract][Full Text] [Related]
2. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort.
Iseki K; Ikemiya Y; Inoue T; Iseki C; Kinjo K; Takishita S
Am J Kidney Dis; 2004 Oct; 44(4):642-50. PubMed ID: 15384015
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of hyperuricemia during cytostatic therapy].
Kolb S; Sailer D; König HJ
Fortschr Med; 1982 Dec; 100(46):2159-61. PubMed ID: 7152443
[TBL] [Abstract][Full Text] [Related]
4. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
Siu YP; Leung KT; Tong MK; Kwan TH
Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic value of the ratio of bone marrow plasma cells in multiple myeloma].
Pasqualetti P; Colantonio D; Casale R
Minerva Med; 1990 Mar; 81(3):129-33. PubMed ID: 2320280
[TBL] [Abstract][Full Text] [Related]
7. Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate.
See LC; Kuo CF; Chuang FH; Li HY; Chen YM; Chen HW; Yu KH
J Rheumatol; 2009 Aug; 36(8):1691-8. PubMed ID: 19531754
[TBL] [Abstract][Full Text] [Related]
8. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
9. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
10. Immunophenotypic analysis of peripheral blood stem cell harvests from patients with multiple myeloma.
Mateo G; Corral M; Almeida J; López-Berges C; Nieto mJ; García-Marcos A; Vázquez L; del Cañizo C; Orfao A; San Miguel JF
Haematologica; 2003 Sep; 88(9):1013-21. PubMed ID: 12969809
[TBL] [Abstract][Full Text] [Related]
11. Influence of Bence-Jones proteins, hyperviscosity, hypercalcemia, hyperuricemia and dehydration on development of renal changes in plasma cell dyscrasias.
Lenert P; Drazen F; Tepavcević P; Pejin D; Curić S; Ilić V; Uzurov V; Popowić S; Zupunski A; Djisalov M
Przegl Lek; 1985; 42(4):384-6. PubMed ID: 4048525
[No Abstract] [Full Text] [Related]
12. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of the serum phosphorus level and its relationship with other prognostic factors in multiple myeloma.
Umeda M; Okuda S; Izumi H; Nagase D; Fujimoto Y; Sugasawa Y; Arai C; Natori K; Katoh M; Kuraishi Y
Ann Hematol; 2006 Jul; 85(7):469-73. PubMed ID: 16528526
[TBL] [Abstract][Full Text] [Related]
14. [Urate-oxidase: a new therapy of cytotoxic-drug-induced hyperuricemia (author's transl)].
Vigo P; Ortolani S; Soldati L; Girardello R; Fleischmann L; Polli EE
Haematologica; 1981 Oct; 66(5):656-66. PubMed ID: 6796473
[No Abstract] [Full Text] [Related]
15. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique.
Orfäo A; García-Sanz R; López-Berges MC; Belén Vidriales M; González M; Caballero MD; San Miguel JF
Cytometry; 1994 Dec; 17(4):332-9. PubMed ID: 7533074
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow changes following chemotherapy for multiple myeloma--a clinicopathological study of biopsy cases.
Kurihara K; Hill W; Burkhardt R; Kettner G; Hashimoto N
Nihon Ketsueki Gakkai Zasshi; 1987 Jul; 50(4):876-89. PubMed ID: 3687331
[No Abstract] [Full Text] [Related]
17. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
18. Hepatic and renal plasma cell lesions in a patient with multiple myeloma in hematological remission.
Galani Z; Viniou N; Kyrtsonis MC; Sachanas S; Antoniou T; Dimopoulou MN; Vassilakopoulos TP; Korkolopoulou P; Nakopoulou L; Patsouris E; Pangalis GA
Anticancer Res; 2007; 27(1B):571-4. PubMed ID: 17348443
[TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
20. Myeloablative therapy for primary resistant multiple myeloma.
Alexanian R; Dimopoulos MA; Delasalle KB; Hester J; Champlin R
Stem Cells; 1995 Aug; 13 Suppl 2():118-21. PubMed ID: 8520499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
